Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence - 16/06/24
Abstract |
Lung cancer is a prevalent malignant tumor and a leading cause of cancer-related fatalities globally. However, current treatments all have limitations. Therefore, there is an urgent need to identify a readily available therapeutic agent to counteract lung cancer development and progression. Luteolin is a flavonoid derived from vegetables and herbs that possesses preventive and therapeutic effects on various cancers. With the goal of providing new directions for the treatment of lung cancer, we review here the recent findings on luteolin so as to provide new ideas for the development of new anti-lung cancer drugs. The search focused on studies published between January 1995 and January 2024 that explored the use of luteolin in lung cancer. A comprehensive literature search was conducted in the SCOPUS, Google Scholar, PubMed, and Web of Science databases using the keywords "luteolin" and "lung cancer." By collecting previous literature, we found that luteolin has multiple mechanisms of therapeutic effects, including promotion of apoptosis in lung cancer cells; inhibition of tumor cell proliferation, invasion and metastasis; and modulation of immune responses. In addition, it can be used as an adjuvant to radio-chemotherapy and helps to ameliorate cancer complications. This review summarizes the structure, natural sources, physicochemical properties and pharmacokinetics of luteolin, and focuses on the anti-lung cancer mechanism of luteolin, so as to provide new ideas for the development of new anti-lung cancer drugs.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Luteolin is one of the flavonoids that can be isolated from vegetables and herbs. |
• | Luteolin has preventive and therapeutic effects on a variety of cancers, including lung cancer. |
• | Luteolin has a variety of anti-lung cancer molecular mechanisms. |
Abbreviations : AIM2, AR, ARE, Bcl-2, CCL2, Cdc42, CDK, DR, EGFR, EMT, ER, FAK, HDAC, IFN-γ, IKK, JNK, LC3, LIMK, MOMP, NF-κB, NK cells, NLRP3, Nrf2, NSCLC, PCNA, Rac1, RhoA, ROS, RTKs, SCLC, SD rats, SIRT, Src, TAMs, TGF-β, TKIs, TNF, TRAILR
Keywords : Luteolin, Phytomedicine, Lung cancer, Pharmacological mechanism, Treatment
Plan
Vol 176
Article 116909- juillet 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?